Showing 5231-5240 of 5621 results for "".
- FDA Approves Eylea for All Stages of Diabetic Retinopathyhttps://modernod.com/news/fda-approves-eylea-for-diabetic-retinopathy/2476580/Regeneron announced that the FDA has approved Eylea (aflibercept) injection to treat all stages of diabetic retinopathy (DR). The FDA approval of Eylea as a treatment for DR was based on 6-month and 1-year results from PANORAMA, a randomized, multicenter, controlled phase 3 trial that enrolled 40
- Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with Omidria Presented at ASCRShttps://modernod.com/news/clinical-study-showing-reduced-incidence-of-cystoid-macular-edema-with-omidria-presented-at-ascrs/2476575/Omeros announced the results of a real-world clinical study showing that its FDA-approved ophthalmic drug Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3% decreases the incidence of postoperative cystoid macular edema (CME), a sight-threatening complication of cataract surgery
- Drusen Characteristics Linked With AMD Risk in Fellow Eyeshttps://modernod.com/news/drusen-characteristics-linked-with-amd-risk-in-fellow-eyes/2476571/In patients with unilateral neovascular age-related macular degeneration (AMD), certain drusen features are associated with conversion to neovascular AMD in the fellow eye, according to a secondary analysis of data from a clinical trial, as re
- Noveome Biotherapeutics Announces Publication of Further Preclinical Results Supporting the Neuroprotective Properties of ST266 in Retinal Ganglion Cellshttps://modernod.com/news/noveome-biotherapeutics-announces-publication-of-further-preclinical-results-supporting-the-neuroprotective-properties-of-st266-in-retinal-ganglion-cells/2476572/Noveome Biotherapeutics announced the publication of preclinical results for ST266, its proprietary, cell-free platform biologic, published in the Journal of Neuro-Ophthalmology. These new results further support the neuroprotective properties of intranasally delivered ST266 in mice with e
- Watchful Waiting OK in Diabetic Macular Edema With Good Visionhttps://modernod.com/news/watchful-waiting-ok-in-diabetic-macular-edema-with-good-vision/2476573/Among patients with center-involved diabetic macular edema (DME) who had good visual acuity, there were no significant differences in vision loss over a 2-year period for those who were initially managed with watchful waiting as compared with those who underwent treatment with laser photocoagulat
- Cholesterol-Lowering Drugs Tied to Reduced Glaucoma Riskhttps://modernod.com/news/cholesterol-lowering-drugs-tied-to-reduced-glaucoma-risk/2476570/High cholesterol is associated with an increased risk of developing glaucoma, but a new study suggests taking statins to lower cholesterol helps to reduce this risk, according to a Reuters
- InstruSafe by Summit Medical Introduces New InstruSafe XL Transport Containerhttps://modernod.com/news/instrusafe-by-summit-medical-introduces-new-instrusafe-xl-transport-container/2476565/InstruSafe by Summit Medical has introduced the new InstruSafe XL Transport Container—the first and only container of its size on the market—designed to accommodate da Vinci SP, Xi Scopes, EndoWrist and other long laparoscopic surgical instruments, according to a company news release. The XL Tra
- Oxurion Issues Financial and Business Updatehttps://modernod.com/news/oxurion-issues-financial-and-business-update/2476562/Oxurion NV issued a business and a financial update for the 3 months ending March 31, 2019. Oxurion is developing a competitive pipeline of disease modifying drug candidates for diabetic eye disease, particularly DME. The Oxurion clinical development pipeline consists of novel products wit
- Mati Therapeutics Phase 2 Nepafenac Evolute Clinical Trial Results Show Significant Postoperative Pain Reductionhttps://modernod.com/news/mati-therapeutics-phase-2-nepafenac-evolute-clinical-trial-results-show-significant-postoperative-pain-reduction/2476558/Mati Therapeutics announced that it has completed a phase 2 clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute sustained ocular punctal plug drug delivery platform. The trial was a multicenter, randomized, masked evaluation of Nepafenac Evolute
- Thomas Walters, MD, Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019https://modernod.com/news/thomas-walters-md-presents-update-on-nicoxs-ncx-470-phase-2-clinical-study-in-podium-presentation-at-ascrs-2019/2476555/Nicox SA announced that ophthalmology key opinion leader and clinical investigator in the ongoing NCX 470 phase 2 clinical study, Thomas Walters, MD, delivered a podium presentation at the annual ASCRS 2019 meeting in San Diego updating on the progress of the NCX 470 phase 2 clinical study in pat